Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Let's see how Iran responds to these Syrian air strikes.
ABVC > 2.28 M share float < 52 week high 18.70 > Company revenue surge in the works!
> $167,000,000. < 2.28 M share float < 52 week high 18.70 > Company revenue surge in the works!
Biggest volume day in company history.
IBRX > ( up 29% ) News ..... The FDA accepted ImmunityBio's resubmission of its Biologics License Application for N-803 as complete.
News > Up 29%today > The FDA accepted ImmunityBio's resubmission of its Biologics License Application for N-803 as complete.
A man in his 40's bought a new Tesla Model S and was out for a nice evening drive. The top was down, the breeze was blowing through what was left of his hair, and he decided to open her up. As the needle jumped up to 90 mph, he suddenly saw flashing red and blue lights behind him. "There's no way they can catch a Tesla," he thought to himself and opened her up further. The needle hit 100, 120.... then the reality of the situation hit him. "What the hell am I doing?" he thought and pulled over. The cop came up to him, took his license without a word, and examined it and the car. "It's been a long day, this is the end of my shift. I don't feel like more paperwork, so if you can give me an excuse for your driving that I haven't heard before, you can go." The guy thinks for a second and says, "Last week my wife ran off with a cop. I was afraid you were trying to give her back." "Have a nice weekend," said the officer.
Is that an FBI agent using a hand jack to move the "Top Secret "files from Biden's garage?
Hunter has been quiet. Probably busy painting more pictures. > Paint by numbers.
Watch attendees accumulate shares on Monday & Tuesday > October 20 - 24th at ESMO Congress 2023
Tesla owners suffering . Range anxiety +++++ lack of charging stations +++++ city folks stealing various metal components of charging stations and selling to scrap yards.
Some of the 44 tutes are Baker Bros. Vanguard, Morgan Stanley, Black Rock .....
Investors are forward looking. The company has been growing revenues. Plenty of research costs, but the ongoing FDA phase III trials are catalysts for higher share price.
Heavy volume @ 86 milly.
ARAV pipeline > https://aravive.com/pipeline/
FOMO / MOMO taking ARAV much higher.
Agree, very huge catalyst:
They are presenting updated clinical trial data from Batiraxcept trials in Renal and Pancreatic cancer this weekend October 20 - 24th at ESMO Congress 2023
Let's see what next week brings... this could be a banger .40 - .80 cents next week if news drops or even just on Anticipation, FOMO and whoever knows on the inside of what is to come and is loading while others are dumping in fear
> ARAV @ .24
Investors might want to bet on Aravive (ARAV), as it has been recently upgraded to a Zacks Rank #1 (Strong Buy). This upgrade primarily reflects an upward trend in earnings estimates, which is one of the most powerful forces impacting stock prices.
Shares of XRTX are trending on Yahoo Finance and moving on remarkably heavy trading volume Friday, despite a lack of company-specific news.
According to data from Benzinga Pro, more than 45 million shares have already been traded in the session, compared to the stock's 100-day average of just over 200 thousand shares.
Xortx Therapeutics is a clinical-stage biotechnology company focused on identifying, developing, and commercializing therapies to treat progressive kidney disease modulated by aberrant purine and uric acid metabolism and uric acid metabolism in orphan disease indications such as ADPKD and T2DN, as well as AKI associated with respiratory virus infection.
Related News: What's Going On With Bitcoin Mining Stocks Marathon Digital And Riot Platforms?
XRTX Price Action: According to Benzinga Pro, Xortx Therapeutics shares are up 52% at 53 cents at the time of publication.
Let's see what happens. The transaction has not closed.
Heading to FDA phase II trial. Long ways to go before FDA phase III approval for marketplace.
Shares of Lipella Pharmaceuticals Inc. (LIPO) rocketed 52.2% higher in very active tracing Friday, after the Pittsburgh-based biotechnology company's investigational new drug application for its oral lichen planus treatment was approved by the U.S. Food and Drug Administration. Trading volume in the stock, which was the best performer on the major U.S. exchanges, blasted higher to 30.7 million shares, compared with the full-day average of about 6,400 shares. The stock has soared 150% in the three days since it last closed below the $1 mark, and has run up 164% amid a six-day winning streak. as Lipella described, OLP is a chronic, inflammatory autoimmune oral muscosal disease. It is a "highly morbid" condition with malignant potential that affects between 1% and 4% of the world population. Lipella's stock has now gained 18.6% over the past three months, but was still 57% below its initial public offering price of $5.75; the company went public on Dec. 20.
-Tomi Kilgore
For more from MarketWatch: http://www.marketwatch.com/newsviewer
CNXA is a great $$$$$ opportunity!
Bought .25 & .26 > MTNB is a great $$$$$ opportunity!
If I were a psychologist, I would tell these eco-anxiety laden kids to grow up , and plant a tree. The leaves thrive on CO2.
Possibly WW3. And Biden has emptied 75% of SPR.
Congrats on MTNB >
Huge conference starts today. > It's exciting to share the ongoing, consistent positive clinical impact of our broad-spectrum, fast-acting oral MAT2203, especially with a major infectious disease conference, IDWeek, kicking off today," said Theresa Matkovits, PhD, Chief Development Officer at Matinas. "We look forward to advancing MAT2203 into a Phase 3 registration trial to evaluate its potential in patients suffering from invasive aspergillosis who have limited or no treatment options. We believe that oral, effective, and safe MAT2203, if approved, would represent a dramatic improvement to current clinical standard of care and become the treatment of choice for patients and physicians battling invasive fungal infections. We are grateful to the participants in our Expanded Access program and to their physicians for recognizing the clinical potential of MAT2203 in treating a broad spectrum of invasive fungal infections."
What a great $$$$$ opportunity!
MTNB
That's funny!
"Joe Biden is neither physically nor cognitively up to the task of Commander in Chief in a crisis. He has more or less disappeared other than offering an occasionally brief appearance where he mumbles about standing with Israel and then vanishes again."
Those ho-tt-ies keep butt-dialing me! Nice trades!
Shiner Brewery started in 1909. Shiner beer is a staple in the Lone Star State, and every drop is brewed out of the Spoetzl Brewery in Shiner, Texas. The brewery is owned by the Gambrinus Company, based in San Antonio, and with each glass of Shiner beer comes a taste of history and pride.
Gritstone Bio shares are trading higher after Piper Sandler maintained an Overweight rating on the stock and raised its price target from $6 to $7. >>>>> GRTS <<<<<
Benzinga
Mulberry Street in lower Manhattan, The spagh-etto!
Share price holding in AH . Let's see how she runs tomorrow.
Maybe government grants don't count in totaling yearly revenues ! > $$$$$
Horrible Revenues > According to MarketWatch, GRTS annual revenue averages $11,000. per employee.
Gritstone bio, Inc. is a biotechnology company. The Company discovers, develops, manufactures and delivers next generation cancer and infectious disease immunotherapy candidates by vaccine vectors, self-amplifying mRNA (samRNA) and chimpanzee adenovirus (ChAd). Its two oncology programs in clinical-stage development are GRANITE, individualized neoantigen-based immunotherapy, and SLATE, an off-the-shelf shared neoantigen-based immunotherapy. It has an infectious disease pipeline, which includes two programs in clinical-stage development: CORAL, a second-generation COVID-19 vaccine program that may have pan-coronavirus potential to protect against future coronavirus pandemics, and an HIV therapeutic/cure vaccine candidate. In oncology, it develops personalized vaccines that aim to destroy tumors through CD8+ (killer) T cell recognition of tumor cells by virtue of their surface display of neoantigens, peptides that are presented on cancer cells when certain mutations occur in tumor DNA.